Diffuse follicle center lymphoma
ICD-10 C82.5 is a billable code used to indicate a diagnosis of diffuse follicle center lymphoma.
Diffuse follicle center lymphoma (DFCL) is a subtype of non-Hodgkin lymphoma characterized by the proliferation of B-lymphocytes within the follicle centers of lymphoid tissues. This condition typically presents with a diffuse pattern of growth, leading to the infiltration of lymph nodes and potentially other organs. Patients may experience lymphadenopathy, splenomegaly, and systemic symptoms. DFCL is often associated with chromosomal translocations involving the BCL2 gene, contributing to its pathogenesis. Staging of DFCL is crucial for determining prognosis and treatment, typically following the Ann Arbor classification system. B-symptoms, which include fever, night sweats, and weight loss, may be present and are indicative of more advanced disease. Treatment protocols often involve chemotherapy regimens, immunotherapy, and in some cases, stem cell transplantation, depending on the stage and overall health of the patient. Regular follow-up and monitoring for disease progression or recurrence are essential components of patient management.
Detailed clinical notes on patient history, physical examination findings, staging, and treatment plans.
Diagnosis of lymphoma, management of chemotherapy side effects, and follow-up care.
Ensure accurate documentation of B-symptoms and treatment response to support coding.
Histopathological reports confirming the diagnosis and subtype of lymphoma.
Biopsy interpretation and staging of lymphomas.
Pathology reports must clearly indicate the subtype to support accurate coding.
Used during treatment of diffuse follicle center lymphoma.
Document the specific chemotherapy regimen and patient response.
Oncology specialists must ensure accurate coding of chemotherapy administration.
Common symptoms include lymphadenopathy, splenomegaly, fever, night sweats, and unexplained weight loss, known as B-symptoms.
Staging is typically done using the Ann Arbor classification system, which assesses the extent of lymph node involvement and the presence of B-symptoms.
Treatment options may include chemotherapy, immunotherapy, and stem cell transplantation, depending on the stage and patient health.
